MRK Stock DD Merck & Co., Inc. Friday, May 2, 2014 11:16:28

New Post Public Reply Private Reply Replies (0) Message Board

May 3, 2014 at 12:16 AM

MRK Merck & Co., Inc. $MRK Company Overview

Stock Message Board http://investorshangout.com/search?q=MRK&...mp;yt1=Go!

Last Updated: Friday, May 2, 2014 11:16:28 PM

Merck & Co., Inc. MRK Current Price and Quotes
Last Price 58.22
Previous Close 59.62 Open 59.47
Daily Range 57.94 - 59.53 52wk Range 44.62 - 59.84
Volume 12,079,563 Dividend 1.76
Average Vol (3m) 11,345,600 Yield 3.023
Merck & Co., Inc. MRK

Merck & Co., Inc. MRK
Merck & Co., Inc. MRK

Merck & Co., Inc. MRK

Merck & Co., Inc. MRK Financials
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 44,033,000 47,267,000 48,047,000 45,987,000
Cost of Revenue 16,954,000 16,446,000 16,871,000 18,396,000
Gross Profit 27,079,000 30,821,000 31,176,000 27,591,000
Operating Expenses

Research and Development 7,503,000 8,168,000 8,467,000 11,111,000
Sales, General and Admin. 11,911,000 12,776,000 13,733,000 13,125,000
Non-Recurring Items 1,709,000 664,000 1,306,000 985,000
Other - - - -
Operating Income 5,956,000 9,213,000 7,670,000 2,370,000
Income From Continuing Operations

Add'l Income/Expense Items (815,000) (1,116,000) (946,000) (1,304,000)
Earnings Before Interest and Tax 5,545,000 8,739,000 7,334,000 1,653,000
Interest Expense - - - -
Earnings Before Tax 5,545,000 8,739,000 7,334,000 1,653,000
Income Tax 1,028,000 2,440,000 942,000 671,000
Minority Interest 113,000 131,000 120,000 121,000
Equity Earnings Unconsolidated Subsidiary 404,000 642,000 610,000 587,000
Net Income Cont. Operations 4,808,000 6,810,000 6,882,000 1,448,000
Non Recurring Events

Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income 4,404,000 6,168,000 6,272,000 861,000
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders 4,404,000 6,168,000 6,272,000 861,000

Merck & Co., Inc. MRK Recent News

May 2, 2014 Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis
May 2, 2014 Approvals from the European Commission and Release of Quarterly Financial Results - Analyst Notes on Merck, Johnson & Johnson, Bristol-Myers Squibb, Teva and AbbVie
May 1, 2014 Technical Data on Equities Reaching New highs -- Research on Banco Santander, Merck, Schlumberger, and Orbital Sciences
Apr 30, 2014 Julie Gerberding Receives AJC Women's Global Leadership Award
Apr 30, 2014 Are Exosomes the Next PD-1 in Cancer Research?
Apr 30, 2014 Research and Markets: Global Osteoporosis Drugs Market Opportunities With Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate
Apr 30, 2014 Freeslate Chemical Development Summit Highlights Best Practices in High Throughput Research and Data Management
Apr 29, 2014 Research and Markets: Global Glaucoma Therapeutics Market 2014-2018: Allergan Inc., Merck & Co. Inc., Novartis AG & Pfizer Dominate the Industry
Apr 29, 2014 University BioParks Serve as Source of Innovation as Pharmaceutical R&D Model Shifts
Apr 29, 2014 Merck Announces First-Quarter 2014 Financial Results

1
2
3
4
5
6
7
8
next >
last >>

MRK Merck & Co., Inc. Research DD Guide

Stock Message Board http://investorshangout.com/search?q=MRK&...mp;yt0=Go!
Stock Quote http://www.otcmarkets.com/stock/MRK/quote
Stock Chart http://www.otcmarkets.com/stock/MRK/chart
Company Info http://www.otcmarkets.com/stock/MRK/company-info
Recent News http://www.otcmarkets.com/stock/MRK/news
Financials http://www.otcmarkets.com/stock/MRK/financials
Filings and Disclosure http://www.otcmarkets.com/stock/MRK/filings
Short Sales http://www.otcmarkets.com/stock/MRK/short-sales
Insider Disclosure http://www.otcmarkets.com/stock/MRK/insider-transactions
Research Reports http://www.otcmarkets.com/stock/MRK/research
Summary http://finance.yahoo.com/q?s=MRK
Historical Prices http://finance.yahoo.com/q/hp?s=MRK+Historical+Prices
Interactive Chart http://finance.yahoo.com/echarts?s=MRK
Basic Chart http://finance.yahoo.com/q/bc?s=MRK+Basic+Chart
Basic Tech. Analysis http://finance.yahoo.com/q/ta?s=MRK+Basic+Tech.+Analysis
Headlines http://finance.yahoo.com/q/h?s=MRK+Headlines
Press Releases http://finance.yahoo.com/q/p?s=MRK+Press+Releases
Company Profile http://finance.yahoo.com/q/pr?s=MRK+Profile
Key Statistics http://finance.yahoo.com/q/ks?s=MRK+Key+Statistics
Industry http://finance.yahoo.com/q/in?s=MRK+Industry
Major Holders http://finance.yahoo.com/q/mh?s=MRK+Major+Holders
Insider Transactions http://finance.yahoo.com/q/it?s=MRK+Insider+Transactions
Insider Roster http://finance.yahoo.com/q/ir?s=MRK+Insider+Roster
Income Statement http://finance.yahoo.com/q/is?s=MRK
Balance Sheet http://finance.yahoo.com/q/bs?s=MRK
Cash Flow http://finance.yahoo.com/q/cf?s=MRK+Cash+Flow&annual
Nasdaq http://www.nasdaq.com/symbol/MRK
Market Watch http://www.marketwatch.com/investing/stock/MRK
Bloomberg http://www.bloomberg.com/quote/MRK:US
Morningstar http://quotes.morningstar.com/stock/s?t=MRK
Bussinessweek http://investing.businessweek.com/research/st...ticker=MRK
Barchart http://www.barchart.com/quotes/stocks/MRK
OTC Short Report http://otcshortreport.com/index.php?index=MRK
Investopedia http://www.investopedia.com/markets/stocks/MRK/?wa=0

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Southern Company Sparks Swift Power Restoration Post-Isaias

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

NARUTO Card Game Set for June 2027 Global Launch

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

AI Drives Major Time Savings in Endoscopy Tech

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...